Onegene Biotechnology
Picking up the most difficult fight
- Headquarters
- Suwon
- Employees
- 11–50
- Business Model
- B2B
- Website
- onegenebt.com
- Last Round
- Series A
- Rounds
- 1
About
Onegene Biotechnology is a South Korean biopharmaceutical company headquartered in Suwon (Gyeonggi Province), developing next-generation multi-specific therapeutics for complex diseases including cancer and metabolic disorders. The company's proprietary UniStac® platform uses enzyme-mediated protein-protein conjugation to enable true plug-and-play multi-targeting drug design with high manufacturability. Its lead pipeline candidates include OGB21502 (a tetra-specific treatment for NASH/liver fibrosis) and OGB23501 (a tri-specific immuno-oncology asset targeting the tumor microenvironment). Onegene raised KRW 40.7 billion and has presented at major conferences including JP Morgan Healthcare, BIO, and EASL.
Summary
Onegene Biotechnology is a Biotech company based in Suwon, South Korea. Investors include Premier Inc., STIC Ventures and Stonebridge Capital.
Tech & App Stack
2 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Unknown
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company